CCL20 and triple-negative breast carcinoma: In addition, treatment with 200 ng/ml CCL20 significantly enhanced cell invasion (Fig. 5g) and stimulated the secretion of MMP-2 and MMP-9 (Fig. 5h) in BT549 and HCC38 cell lines, which are basal-like/triple-negative breast cancer cell lines, as is the MDA-MB-231 cell line.